Risk stratification of gastrointestinal stromal tumors by Nanostring gene expression profiling.
Gastrointestinal stromal tumors
Gene expression profiling
Risk stratification
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
05
10
2021
accepted:
12
01
2022
pubmed:
29
1
2022
medline:
20
5
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
The risk assessment classification schemes for gastrointestinal stromal tumors (GIST) include tumor site, size, mitotic count and variably tumor rupture. Heterogeneity in high-risk GIST poses limitations for current classification schemes. This study aims to demonstrate the clinical utility of risk stratification by gene expression profiling (GEP) using Nanostring technology. Fifty-six GIST cases were analyzed using a 231 gene expression panel. GEP results were correlated with clinical and pathological data. The prognostic performance was assessed in 34 patients with available survival data using ROC curves, Kaplan-Meier survival curves and compared with traditional risk assessment schemes. Volcano plot analysis identified seven genes with significantly higher expression (FDR < .0.05) in high-risk than in non-high-risk tumors, namely TYMS, CDC2, TOP2A, CCNA2, E2F1, PCNA, and BIRC5. Together, these transcripts exhibited significantly higher expression in high-risk tumors than in intermediate (P < 0.01), low (P < 0.001), and very low (P = 0.01) risk tumors. Receiver-operating characteristic curve analysis demonstrated area under the curve (AUC) to be 0.858 for the separation of high-risk and non-high-risk tumors. Kaplan-Meier survival analysis demonstrated improved risk stratification (log-rank test P < 0.001) compared to the current risk assessment classification (P = 0.231). In addition to current clinical and histology-based risk classification for patients with GIST, gene expression may offer complementary prognostic information.
Identifiants
pubmed: 35089395
doi: 10.1007/s00432-022-03924-3
pii: 10.1007/s00432-022-03924-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1325-1336Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Andersson J et al (2006) Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130(6):1573–1581. https://doi.org/10.1053/j.gastro.2006.01.043
doi: 10.1053/j.gastro.2006.01.043
pubmed: 16697720
Arne G et al (2011) Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer 129(5):1149–1161. https://doi.org/10.1002/ijc.25755
doi: 10.1002/ijc.25755
pubmed: 21064103
Ashburner M et al (2000) Gene ontology: tool for the unification of biology. the Gene Ontology Consortium. Nat Genet 25(1):25–29. https://doi.org/10.1038/75556
doi: 10.1038/75556
pubmed: 10802651
pmcid: 3037419
Astolfi A et al (2010) A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest 90(9):1285–1294. https://doi.org/10.1038/labinvest.2010.110
doi: 10.1038/labinvest.2010.110
pubmed: 20548289
Bankhead P et al (2017) QuPath: Open source software for digital pathology image analysis. Sci Rep 7(1):16878. https://doi.org/10.1038/s41598-017-17204-5
doi: 10.1038/s41598-017-17204-5
pubmed: 29203879
pmcid: 5715110
Blanke CD et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625. https://doi.org/10.1200/JCO.2007.13.4403
doi: 10.1200/JCO.2007.13.4403
pubmed: 18235121
Doyle LA, Hornick JL (2014) Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase. Histopathology 64(1):53–67. https://doi.org/10.1111/his.12302
doi: 10.1111/his.12302
pubmed: 24117705
El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M (2000) DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 60(14):3899–903. PMID: 10919666. https://www.ncbi.nlm.nih.gov/pubmed/10919666 . Accessed 15 July 2000
Fabregat A et al (2018) The reactome pathway knowledgebase. Nucleic Acids Res 46(D1):D649–D655. https://doi.org/10.1093/nar/gkx1132
doi: 10.1093/nar/gkx1132
pubmed: 29145629
Fletcher CD et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33(5):459–465. https://doi.org/10.1053/hupa.2002.123545
doi: 10.1053/hupa.2002.123545
pubmed: 12094370
Gastrointestinal Stromal Tumor Meta-Analysis G (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28(7):1247–1253. https://doi.org/10.1200/JCO.2009.24.2099
doi: 10.1200/JCO.2009.24.2099
Geddert H et al (2017) Epigenetic regulation of CD133 in gastrointestinal stromal tumors. Am J Clin Pathol 147(5):515–524. https://doi.org/10.1093/ajcp/aqx028
doi: 10.1093/ajcp/aqx028
pubmed: 28398518
Geiss GK et al (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26(3):317–325. https://doi.org/10.1038/nbt1385
doi: 10.1038/nbt1385
pubmed: 18278033
Gnant M et al (2014) Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25(2):339–345. https://doi.org/10.1093/annonc/mdt494
doi: 10.1093/annonc/mdt494
pubmed: 24347518
Gumurdulu D et al (2007) Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters. World J Gastroenterol 13(3):426–431. https://doi.org/10.3748/wjg.v13.i3.426
doi: 10.3748/wjg.v13.i3.426
pubmed: 17230613
pmcid: 4065899
Gunawan B et al (2007) An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J Pathol 211(4):463–470. https://doi.org/10.1002/path.2128
doi: 10.1002/path.2128
pubmed: 17226762
Hara R et al (2015) Microarray analysis reveals distinct gene set profiles for gastric and intestinal gastrointestinal stromal tumors. Anticancer Res 35(6):3289–3298. PMID: 26026088. https://www.ncbi.nlm.nih.gov/pubmed/26026088 . Accessed June 2015
Heinrich MC et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764–4774. https://doi.org/10.1200/JCO.2006.06.2265
doi: 10.1200/JCO.2006.06.2265
pubmed: 16954519
Henze J et al (2012) p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS ONE 7(5):e37776. https://doi.org/10.1371/journal.pone.0037776
doi: 10.1371/journal.pone.0037776
pubmed: 22662219
pmcid: 3360609
Huang HY et al (2007) A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 141(6):748–756. https://doi.org/10.1016/j.surg.2007.01.024
doi: 10.1016/j.surg.2007.01.024
pubmed: 17560251
Joensuu H et al (2014) Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer 120(15):2325–2333. https://doi.org/10.1002/cncr.28669
doi: 10.1002/cncr.28669
pubmed: 24737415
Lasota J, Miettinen M (2008) Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53(3):245–266. https://doi.org/10.1111/j.1365-2559.2008.02977.x
doi: 10.1111/j.1365-2559.2008.02977.x
pubmed: 18312355
Liu XH, Bai CG, Xie Q, Feng F, Xu ZY, Ma DL (2005) Prognostic value of KIT mutation in gastrointestinal stromal tumors. World J Gastroenterol 11(25):3948–3952. https://doi.org/10.3748/wjg.v11.i25.3948
doi: 10.3748/wjg.v11.i25.3948
pubmed: 15991300
pmcid: 4504903
Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23(2):70–83. https://doi.org/10.1053/j.semdp.2006.09.001
doi: 10.1053/j.semdp.2006.09.001
pubmed: 17193820
Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29(1):52–68. https://doi.org/10.1097/01.pas.0000146010.92933.de
doi: 10.1097/01.pas.0000146010.92933.de
pubmed: 15613856
Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30(4):477–489. https://doi.org/10.1097/00000478-200604000-00008
doi: 10.1097/00000478-200604000-00008
pubmed: 16625094
Mootha VK et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267–273. https://doi.org/10.1038/ng1180
doi: 10.1038/ng1180
pubmed: 12808457
Nakamura N et al (2005) Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 36(7):828–837. https://doi.org/10.1016/j.humpath.2005.03.012
doi: 10.1016/j.humpath.2005.03.012
pubmed: 16084954
Nannini M, Urbini M, Astolfi A, Biasco G, Pantaleo MA (2017) The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST). J Transl Med 15(1):113. https://doi.org/10.1186/s12967-017-1212-x
doi: 10.1186/s12967-017-1212-x
pubmed: 28535771
pmcid: 5442859
Nielsen T et al (2014) Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 14:177. https://doi.org/10.1186/1471-2407-14-177
doi: 10.1186/1471-2407-14-177
pubmed: 24625003
pmcid: 4008304
Nilsson B et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 103(4):821–829. https://doi.org/10.1002/cncr.20862
doi: 10.1002/cncr.20862
pubmed: 15648083
Pantaleo MA et al (2014) Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. Clin Sarcoma Res 4:9. https://doi.org/10.1186/2045-3329-4-9
doi: 10.1186/2045-3329-4-9
pubmed: 25143820
pmcid: 4138414
Pantaleo MA et al (2017) Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST. Mol Cancer Res 15(5):553–562. https://doi.org/10.1158/1541-7786.MCR-16-0376
doi: 10.1158/1541-7786.MCR-16-0376
pubmed: 28130400
Reis PP et al (2011) mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 11:46. https://doi.org/10.1186/1472-6750-11-46
doi: 10.1186/1472-6750-11-46
pubmed: 21549012
pmcid: 3103428
Ricci R et al (2018) Telocytes are the physiological counterpart of inflammatory fibroid polyps and PDGFRA-mutant GISTs. J Cell Mol Med 22(10):4856–4862. https://doi.org/10.1111/jcmm.13748
doi: 10.1111/jcmm.13748
pubmed: 30117724
pmcid: 6156396
Saponara M et al (2015) Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRalpha genotype evaluated by next generation sequencing (NGS). Oncotarget 6(39):42243–42257. https://doi.org/10.18632/oncotarget.6278
doi: 10.18632/oncotarget.6278
pubmed: 26544626
pmcid: 4747222
Schaefer IM et al (2017) MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun 8:14674. https://doi.org/10.1038/ncomms14674
doi: 10.1038/ncomms14674
pubmed: 28270683
pmcid: 5344969
Schmieder M et al (2016) Comparison of different risk classification systems in 558 patients with gastrointestinal stromal tumors after R0-resection. Front Pharmacol 7:504. https://doi.org/10.3389/fphar.2016.00504
doi: 10.3389/fphar.2016.00504
pubmed: 28082898
pmcid: 5187374
Skubitz KM, Geschwind K, Xu WW, Koopmeiners JS, Skubitz AP (2016) Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors. J Transl Med 14:51. https://doi.org/10.1186/s12967-016-0802-3
doi: 10.1186/s12967-016-0802-3
pubmed: 26873324
pmcid: 4752787
Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Bulusu VR (2016) Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol 40:39–46. https://doi.org/10.1016/j.canep.2015.10.031
doi: 10.1016/j.canep.2015.10.031
pubmed: 26618334
Subramanian A et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. https://doi.org/10.1073/pnas.0506580102
doi: 10.1073/pnas.0506580102
pubmed: 16199517
pmcid: 1239896
Takahashi A et al (2014) Analysis of gene expression profiles of soft tissue sarcoma using a combination of knowledge-based filtering with integration of multiple statistics. PLoS ONE 9(9):e106801. https://doi.org/10.1371/journal.pone.0106801
doi: 10.1371/journal.pone.0106801
pubmed: 25188299
pmcid: 4154757
Trimboli P, Sorrenti S (2009) Low value of color flow-doppler in predicting malignancy of thyroid follicular neoplasms. Diagn Cytopathol 37(5):391–392. https://doi.org/10.1002/dc.21050
doi: 10.1002/dc.21050
pubmed: 19217062
Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG (2005) Gastrointestinal stromal tumors in Iceland, 1990–2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117(2):289–293. https://doi.org/10.1002/ijc.21167
doi: 10.1002/ijc.21167
pubmed: 15900576
Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL (2013) Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 26(2):289–294. https://doi.org/10.1038/modpathol.2012.153
doi: 10.1038/modpathol.2012.153
pubmed: 22955521
Wang Y et al (2014) Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet 46(6):601–606. https://doi.org/10.1038/ng.2974
doi: 10.1038/ng.2974
pubmed: 24793134
pmcid: 4225780
Wozniak A et al (2007) Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer 46(3):261–276. https://doi.org/10.1002/gcc.20408
doi: 10.1002/gcc.20408
pubmed: 17171690
Yen CC et al (2012) Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker. Ann Surg Oncol 19(11):3491–3499. https://doi.org/10.1245/s10434-012-2389-0
doi: 10.1245/s10434-012-2389-0
pubmed: 22588468
Zhao X, Yue C (2012) Gastrointestinal stromal tumor. J Gastrointest Oncol 3(3):189–208. https://doi.org/10.3978/j.issn.2078-6891.2012.031
doi: 10.3978/j.issn.2078-6891.2012.031
pubmed: 22943011
pmcid: 3418531